Armour Thyroid vs Tirosint: Switching Between Natural Desiccated Thyroid and Levothyroxine Gel Caps

What Each Drug Actually Contains

Armour Thyroid is a desiccated porcine thyroid extract that delivers a fixed combination of T4 (levothyroxine) and T3 (liothyronine). Each grain (60 mg) contains approximately 38 mcg of T4 and 9 mcg of T3, yielding a T4:T3 ratio of roughly 4.2:1. This ratio does not match the human thyroid's native output of approximately 14:1, which means patients on Armour receive proportionally more T3 than their own gland would produce.

Tirosint takes an entirely different approach. It is a synthetic levothyroxine (T4 only) formulated as a liquid inside a gelatin capsule. The capsule contains just four inactive ingredients: gelatin, glycerin, water, and a trace of dye. Standard levothyroxine tablets, by comparison, contain multiple fillers, binders, and excipients that can interfere with absorption in sensitive patients. The Vita et al. 2014 trial demonstrated that this simplified formulation achieved more consistent TSH normalization in patients with impaired gastric absorption, including those on proton pump inhibitors and those with prior bariatric surgery.

The core distinction matters for anyone considering a switch. Moving from Armour to Tirosint means losing the T3 component entirely. Moving the other direction means gaining T3 but also accepting greater variability in hormone levels throughout the day.

Head-to-Head Evidence: What the Trials Show

No randomized controlled trial has directly compared Armour Thyroid to Tirosint. The existing evidence requires triangulation across studies that tested each drug against standard levothyroxine tablets.

The Hoang et al. 2013 crossover trial (N=70) randomized hypothyroid patients to either NDT (natural desiccated thyroid) or levothyroxine for 16 weeks, then switched them to the opposite treatment. TSH levels were statistically similar between groups. The NDT group lost an average of 3 pounds more than the levothyroxine group, and 48.6% of participants preferred NDT compared to 18.6% who preferred levothyroxine (P = 0.002). The authors noted that despite this preference signal, "there was no difference in symptoms or neurocognitive function" between treatments.

The Vita et al. 2014 study examined Tirosint's gel cap formulation in patients who had persistently elevated TSH despite adequate doses of tablet levothyroxine. These were patients with documented absorption barriers. After switching to the liquid gel cap at the same microgram dose, TSH dropped into the reference range in the majority of patients without dose adjustment. The study confirmed that Tirosint's absorption advantage is most pronounced in patients taking PPIs, those with celiac disease, atrophic gastritis, or post-surgical anatomy changes.

For patients without absorption issues, both Armour Thyroid and Tirosint perform comparably to standard levothyroxine in controlling TSH. The preference question is where things diverge.

Dose Conversion When Switching

Getting the dose right is the most clinically consequential step in any switch between these two medications. The conversion is not a simple 1:1 calculation because Armour contains T3, which is roughly three to four times more metabolically potent per microgram than T4.

The standard conversion framework used by most endocrinologists:

1 grain (60 mg) Armour Thyroid ≈ 88 to 100 mcg levothyroxine (Tirosint)

This range accounts for the T3 contribution. A patient on 2 grains (120 mg) of Armour would typically convert to approximately 175 to 200 mcg of Tirosint. The American Thyroid Association (ATA) 2014 guidelines recommend using the lower end of the conversion range in older patients and those with cardiac risk factors, because the abrupt loss of T3 from Armour is partially offset by the more consistent T4 absorption from Tirosint.

When switching from Tirosint to Armour, the conversion runs in reverse. A patient on 100 mcg of Tirosint would start at 1 grain (60 mg) of Armour. The clinician should warn the patient that T3 levels will spike within 2 to 4 hours after each Armour dose. This can cause transient palpitations or anxiety in sensitive individuals.

Regardless of direction, TSH should be rechecked at 6 to 8 weeks post-switch. Free T4 and free T3 levels add useful context, particularly for patients coming off Armour who want confirmation that their T3 levels remain adequate on T4-only therapy.

Who Should Consider Switching from Armour to Tirosint

Not every patient on Armour Thyroid needs to switch. But several clinical scenarios make the move worth discussing.

Absorption problems on any tablet formulation. Patients who take PPIs such as omeprazole, those with celiac disease, or those who have undergone Roux-en-Y gastric bypass frequently struggle to absorb tablet-based medications. The Vita et al. data showed that Tirosint's gel cap bypasses many of these barriers. If a patient is on Armour and still running a TSH above target, the issue may not be the hormone itself but the delivery format.

Erratic TSH readings. Armour Thyroid's T3 content causes TSH to fluctuate based on timing of the blood draw relative to the dose. A TSH drawn 2 hours after Armour may read artificially low, while a trough level at 24 hours may read high. Switching to Tirosint eliminates this T3-driven variability and makes monitoring more straightforward.

Cardiac concerns. The ATA guidelines specifically caution against T3-containing preparations in patients with atrial fibrillation, coronary artery disease, or heart failure. The T3 peaks from Armour can exacerbate arrhythmias. Tirosint provides steady-state T4 without the cardiovascular spikes.

Patients who simply feel fine on synthetic T4. Some patients were started on Armour years ago based on a preference that no longer applies. If symptoms are well-controlled and the patient has no objection, simplifying to a single-ingredient medication reduces polypharmacy risk.

Who Should Consider Switching from Tirosint to Armour

The reverse switch also has valid indications, though the evidence base is thinner.

Persistent symptoms despite normal TSH on levothyroxine. The Hoang et al. trial documented a measurable patient preference for NDT. Some patients report better energy, mood, and cognitive clarity on combination T4/T3 therapy. The 2012 European Thyroid Association (ETA) guidelines acknowledged that a subgroup of hypothyroid patients may benefit from combination therapy, though they stopped short of recommending it as first-line.

Poor T4-to-T3 conversion. Patients with the DIO2 Thr92Ala polymorphism (present in roughly 16% of the population) may convert T4 to T3 less efficiently. A 2009 study in the Journal of Clinical Endocrinology and Metabolism found that carriers of this variant reported worse psychological well-being on levothyroxine monotherapy. For these patients, the T3 in Armour may address a genuine biochemical gap.

Patient preference. The Hoang trial's 48.6% preference rate for NDT is not trivial. When a patient has tried synthetic T4 and reports feeling "flat" or "not themselves," a supervised trial of Armour Thyroid is a reasonable clinical experiment. The key is to monitor closely. Set a 12-week trial period with clear symptom endpoints and scheduled lab draws.

How to Execute the Switch Safely

A structured approach minimizes risk during any thyroid medication transition.

Step 1: Baseline labs. Draw TSH, free T4, and free T3 on the current medication, timed consistently (ideally first thing in the morning before that day's dose). This establishes the comparison point.

Step 2: Calculate the conversion dose. Use the 1 grain = 88 to 100 mcg equivalence. For patients over 65 or with cardiac history, start at the lower end. For younger patients without comorbidities, the midpoint (approximately 94 mcg, which rounds to a 100 mcg Tirosint capsule) is appropriate.

Step 3: Timing and food interactions. Both Armour and Tirosint should be taken on an empty stomach, 30 to 60 minutes before food. Tirosint has one advantage here: the gel cap formulation shows less sensitivity to co-administration with coffee compared to standard levothyroxine tablets, though the manufacturer still recommends fasting administration.

Step 4: Recheck labs at 6 to 8 weeks. The ATA recommends waiting a full 6 weeks for TSH to reach steady state after any dose or formulation change. Checking earlier may produce misleading results.

Step 5: Adjust and recheck. If TSH is above target after switching to Tirosint, increase by 12.5 to 25 mcg. If below target after switching to Armour, reduce by half a grain (30 mg). Recheck in another 6 weeks.

Step 6: Address the T3 gap. Patients switching from Armour to Tirosint who previously felt well on combination therapy may need a separate low-dose liothyronine prescription (typically 5 to 10 mcg daily) to replace the T3 they lost. This should be a deliberate clinical decision, not an afterthought.

Absorption and Bioavailability Differences

The way each drug enters the bloodstream is where their pharmacokinetic profiles diverge most sharply.

Armour Thyroid is a pressed tablet with standard pharmaceutical excipients. Its absorption follows the same general pattern as other tablet thyroid medications: roughly 40 to 80% of the T4 component and 95% of the T3 component reach systemic circulation when taken in the fasting state. The ATA estimates that co-ingestion with food can reduce T4 absorption by up to 40%.

Tirosint's liquid gel cap was specifically engineered to address absorption variability. The T4 is dissolved in a liquid matrix rather than compressed into a powder. This matters for patients with altered gastric pH (from PPIs or atrophic gastritis) because levothyroxine requires an acidic environment to dissolve from tablet form. The gel cap arrives pre-dissolved. In the Vita et al. study, patients with documented malabsorption who failed on tablet levothyroxine achieved target TSH on Tirosint at the same microgram dose, meaning the bioavailability improvement was clinically meaningful.

For a patient with normal GI function and no medication interactions, the absorption difference between these formulations may be negligible. The practical advantage of Tirosint's gel cap emerges specifically in complex patients.

Cost and Insurance Considerations

Cost can determine whether a switch is sustainable.

Tirosint is a branded medication without a generic equivalent (as of 2026). Cash prices range from $50 to $120 per month depending on dose and pharmacy. Tirosint-SOL (the liquid solution form) runs even higher, often $150 to $200 per month without coverage. Most commercial insurance plans cover Tirosint with a specialty-tier copay, but prior authorization is frequently required. The typical PA requirement: documented failure or intolerance of generic levothyroxine tablets.

Armour Thyroid itself is a branded product from Allergan, priced at approximately $30 to $80 per month. Generic equivalents include NP Thyroid (Acella Pharmaceuticals) and WP Thyroid (RLC Labs), which range from $20 to $60 per month. Insurance coverage for NDT products varies widely. Some formularies classify them as non-preferred or exclude them entirely, citing the ATA's recommendation of levothyroxine as first-line therapy.

Patients switching from Armour to Tirosint should verify coverage before filling. A prior authorization denial can be appealed with documentation of malabsorption or tablet intolerance.

Monitoring After the Switch

The post-switch monitoring protocol is identical regardless of direction.

TSH alone is insufficient for patients who care about symptoms, not just numbers. The ATA 2014 guidelines recommend TSH as the primary monitoring tool but acknowledge that free T4 and free T3 provide additional context, particularly when clinical symptoms do not match the TSH value.

Dr. Antonio Bianco, a thyroid researcher at the University of Chicago and author of multiple studies on T4/T3 combination therapy, has stated: "TSH is a pituitary hormone, not a tissue-level marker. Patients can have a normal TSH and still have inadequate T3 at the cellular level, particularly those with deiodinase polymorphisms."

For patients switching from Armour to Tirosint, free T3 levels deserve particular attention. A drop in free T3 below the lower third of the reference range, combined with new symptoms of fatigue or cognitive slowing, suggests the patient may benefit from adding low-dose liothyronine.

For patients switching from Tirosint to Armour, the T3 component in Armour may suppress TSH more aggressively. A TSH of 0.1 to 0.4 mIU/L on Armour does not necessarily indicate overtreatment if free T4 and free T3 are within range and the patient has no hyperthyroid symptoms. The ETA consensus statement noted this phenomenon and recommended against reflexive dose reduction based on a mildly suppressed TSH alone in patients on combination therapy.

Check thyroid function at 6 weeks, 12 weeks, and 6 months post-switch. Stable labs at the 6-month mark generally allow a return to annual monitoring.